表紙
市場調査レポート

多発性骨髄腫(カーラー病):パイプライン製品の分析

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229718
出版日 ページ情報 英文 1031 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
多発性骨髄腫(カーラー病):パイプライン製品の分析 Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016
出版日: 2016年06月15日 ページ情報: 英文 1031 Pages
概要

多発性骨髄腫とは、悪性形質細胞が骨髄内部で増殖し、異常な量の特殊タンパク質を産出する、という種類のがんです。その病因についてはまだ明らかにされていません。高齢者が主な発症者となっています。主な症状として、貧血症や出血、神経損傷、皮膚病変、骨の圧痛・疼痛、腎不全などが挙げられます。主な治療法として、化学療法や放射線治療、免疫抑制剤、外科手術などがあります。

当レポートでは、世界各国での多発性骨髄腫(カーラー病)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

多発性骨髄腫の概要

治療薬の開発

  • 多発性骨髄腫向けパイプライン製品:概要
  • 多発性骨髄腫向けパイプライン製品:比較分析

各企業で開発中の多発性骨髄腫治療薬

大学/研究機関で研究中の多発性骨髄腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

多発性骨髄腫治療薬:開発中の製品の一覧(企業別)

多発性骨髄腫治療薬:研究中の製品の一覧(大学/研究機関別)

多発性骨髄腫治療薬の開発に従事している企業

  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Seattle Genetics, Inc.
  • Biotest AG
  • Merck & Co., Inc.
  • Gamida Cell Ltd.
  • BioLineRx, Ltd.
  • Amorfix Life Sciences Ltd.
  • ZIOPHARM Oncology, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • 日本化薬
  • 小野薬品工業
  • Sigma-Tau S.p.A.
  • アステラス製薬
  • 大鵬薬品工業
  • Santaris Pharma A/S
  • Celgene Corporation
  • Onyx Pharmaceuticals, Inc.
  • XTL Biopharmaceuticals Ltd.
  • MannKind Corporation
  • Merck KGaA
  • 4SC AG
  • EntreMed, Inc.
  • Gentium S.p.A.
  • AEterna Zentaris Inc.
  • ImmunoCellular Therapeutics, Ltd.
  • Immunomedics, Inc.
  • Compugen Ltd.
  • Patrys Limited.
  • Curis, Inc.
  • BioInvent International AB
  • JW Pharmaceutical Corporation
  • Innate Pharma SA
  • Transgene Biotek Limited
  • Cellerant Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Chroma Therapeutics Ltd.
  • CIMAB S.A.
  • Actinium Pharmaceuticals, Inc.
  • Acceleron Pharma, Inc.
  • Priaxon AG
  • Hutchison MediPharma Limited
  • Vivolux AB
  • Altor BioScience Corporation
  • Coronado Biosciences, Inc.
  • Vaccinex, Inc.
  • キャンバス
  • Axelar AB
  • Onconova Therapeutics, Inc.
  • Selexys Pharmaceuticals Corporation
  • Immune System Therapeutics Ltd.
  • Concert Pharmaceuticals, Inc.
  • Enceladus Pharmaceuticals BV
  • Immunocore Limited
  • Tragara Pharmaceuticals, Inc.
  • Pharma Mar, S.A.
  • KaloBios Pharmaceuticals, Inc.
  • AB Science
  • Anthera Pharmaceuticals, Inc.
  • CureTech Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Janssen Biotech, Inc.
  • Elara Pharmaceuticals GmbH
  • Zyngenia, Inc.
  • Molecular Templates Inc.
  • 大塚ホールディングス
  • Gliknik, Inc.
  • Celleron Therapeutics Ltd
  • Immunovative Therapies, Ltd.
  • Targazyme, Inc.
  • Advancell
  • Vaxil Bio Therapeutics Ltd.
  • Igenica, Inc.
  • Selvita S.A.
  • Karyopharm Therapeutics, Inc.
  • APIM Therapeutics AS
  • Kancera AB
  • Jasco Pharmaceuticals, LLC.
  • OncoPep Inc.
  • Rhizen Pharmaceuticals SA
  • Formula Pharmaceuticals, Inc.
  • Tolero Pharmaceuticals, Inc.
  • Modulation Therapeutics, Inc.
  • AbbVie Inc.
  • cCAM Biotherapeutics Ltd.
  • BioNovion B.V.
  • Senhwa Biosciences

多発性骨髄腫:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル(計167種類)

  • lenalidomide
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • クエン酸イクサゾミブ
  • エロツズマブ
  • ボリノスタット
  • レナリドマイド
  • マシチニブ
  • ペプチドワクチン
  • 塩酸アルボシジブ
  • タバルマブ
  • テセモチド
  • ブレンツキシマブベドチン
  • ダラツムマブ
  • ソタテルセプト
  • AT-9283
  • AT-7519
  • PAT-SM6
  • ベムラフェニブ
  • IST-1097
  • IPH-2101
  • ダリナパルシン
  • メルファラン
  • indatuximab ravtansine
  • BI-505
  • シルツキシマブ
  • ピジリズマブ
  • 乳酸ドビチニブ
  • PM-00104
  • ImMucin
  • NK-012
  • レナリドマイド
  • ウィルムス腫瘍遺伝子mRNA形質移入自家樹状細胞ワクチン
  • 同種異系骨髄腫ワクチン+骨髄活性化浸潤リンパ球
  • ベバシズマブ
  • BHQ-880
  • BL-8040
  • GL-0817
  • CHR-3996
  • オプロゾミブ
  • デフィブロタイド
  • KB-004
  • hTERTワクチン+肺炎球菌結合型ワクチン
  • AlloStim
  • IMMU-110
  • CC-223
  • ALT-803
  • 応用型細胞媒介治療向けナチュラルキラー細胞製品
  • アフレシルチブ+トラメチニブ
  • PVX-410
  • GSK-525762
  • NY-ESO-1・LAGE-1専用・TCR増強型自家T細胞の発現
  • DNA融合ワクチン
  • TAS-120
  • 塩酸ペボネジスタット
  • ENMD-2076
  • 4SC-202
  • TG-02
  • リゴセルチブ・ナトリウム
  • MLN-0128
  • CXD-101
  • フィクラツズマブ
  • SST-0001
  • κ-CD28 T細胞
  • マリゾミブ
  • ニボルマブ
  • OPB-51602
  • CX-5461
  • CUDC-907
  • ペンブロリズマブ
  • CC-115
  • 遺伝子組み換え型ヒトエリトロポエチン
  • CC-122
  • イットリウムY90抗CD45モノクローナル抗体BC8+シクロスポリン+リン酸フルダラビン+ミコフェノール酸モフェチル+造血幹細胞自家移植+放射線治療
  • FPI-01
  • KPT-330
  • Iomab-B
  • 遺伝子組み換え型T細胞
  • CB-839
  • アカデシン
  • ICT-69
  • ICT-037
  • blisibimod
  • MDX-1458
  • AXL-1717
  • SelK2-Anti-PSGL-1
  • NPI-1342
  • ABT-737
  • 多発性骨髄腫向け医薬品
  • 多発性骨髄腫向けCGEN-928標的モノクローナル抗体
  • MKC-204
  • VX-30
  • CBS-9106
  • Multiple Myeloma BiTE
  • EZN-3892
  • MRx-102
  • CWP-232291
  • ImmTAC Targeting NY ESO
  • CNDO-109
  • TBL-0306-M
  • EL-102
  • EL-103
  • MTI-101
  • FV-162
  • ATX-101
  • EL-101
  • CTP-221
  • ARC-205
  • CM-10
  • MBC-11
  • ER Stress 2-Series Program
  • TGR-1202
  • 多発性骨髄腫向けCD48発現細胞阻害用モノクローナル抗体
  • TAS-2985
  • GF-15
  • IGN-003
  • APRIL標的モノクローナル抗体
  • IGN-523
  • 多発性骨髄腫向け小分子
  • リトナビルのアナログ(類似体)
  • インターフェロンα-2bのバイオシミラー
  • 多発性骨髄腫向けMMSET/NSD2阻害用小分子
  • 多発性骨髄腫向けPimキナーゼ2阻害用小分子
  • SEL24-B489
  • ASC-102
  • CR-2408
  • REM-1086
  • Mcl-1阻害剤
  • 第一世代のレオウイルス弱毒株
  • JP-11646
  • Bi-Specific TRAIL Receptor-2 Zybodies
  • 腫瘍感作型ナチュラルキラー細胞
  • 多発性骨髄腫・充実性腫瘍向けアロステリック・プロテアソーム阻害用小分子
  • ヌクレオシドのアナログ(類似体)
  • 多発性骨髄腫向けペプチド
  • p62-ZZ阻害剤
  • HCI-1684
  • TP-4207
  • ELR-510444
  • KPT-276
  • BVB-808 + BGJ-398
  • 14-F7モノクローナル抗体(MAb)
  • Sangivamycin-Like Molecule-6
  • VLX-1570
  • HMPL-453
  • FV-214
  • JS-K
  • 酢酸デキタメタゾン・リポソーマ
  • BQS-481
  • VAC-2
  • がん幹細胞抗体プログラム
  • Anti-CD38
  • 抗CD28モノクローナル抗体
  • IPSI-001
  • リトナビルのアナログ(類似体)
  • SHIP1阻害剤
  • 多発性骨髄腫向け医薬品
  • 多発性骨髄腫向け医薬品
  • 多発性骨髄腫向けカルニチンパルミトイルトランスフェラーゼ-1阻害剤
  • 多発性骨髄腫向けリパーゼ阻害剤
  • 血液悪性腫瘍向け小分子
  • UV-4
  • 免疫疾患・腫瘍向けCXCR4作動薬
  • がん向けセントラルメモリーT細胞療法
  • 免疫優勢非主要組織適合性抗原プログラム
  • Syrbactins
  • 多発性骨髄腫・神経芽細胞腫向けHDAC阻害剤
  • ペリホシン
  • BNV-215

多発性骨髄腫治療薬:パイプライン製品の最新動向

多発性骨髄腫治療薬:開発が休止状態の製品

多発性骨髄腫治療薬:開発が中止された製品

多発性骨髄腫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8160IDB

Summary

Global Markets Direct's, 'Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2016', provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)
  • The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Multiple Myeloma (Kahler Disease) Overview
  • Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies
  • Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes
  • Multiple Myeloma (Kahler Disease) - Pipeline Products Glance
  • Multiple Myeloma (Kahler Disease) - Products under Development by Companies
  • Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes
  • Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
  • Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
  • Drug Profiles
  • Multiple Myeloma (Kahler Disease) - Dormant Projects
  • Multiple Myeloma (Kahler Disease) - Discontinued Products
  • Multiple Myeloma (Kahler Disease) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2016
  • Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH , H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by APO-T B.V., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by BioInvent International AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by ConverGene, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Curis, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime B.V., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science s.r.l., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology, LLC., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunocore Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Immunomic Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kancer Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Kezar Life Sciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Medivation, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co., Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Midatech Pharma US Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax, LLC, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MolMed S.p.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar, S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Progenra, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quest PharmaTech Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx, S.L., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Rodos BioTarget GmbH, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Selvita S.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Synta Pharmaceuticals Corp., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by TG Therapeutics, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Limited, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Verastem, Inc., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad, H1 2016
  • Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H1 2016
  • Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H1 2016
  • Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2016
  • Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top